Search

Displaying results 8061 - 8070 of 10000 in total
  1. Drug

    ASP-8731

    go.drugbank.com/drugs/DB17696
    Investigational

    Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.[L46093]

  2. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    It is being developed by Avicena Group, Inc.

  3. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

  4. Drug

    PF-03882845

    go.drugbank.com/drugs/DB11814
    Investigational

    PF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type 2 Diabetic Nephropathy.

  5. Drug

    BMS-830216

    go.drugbank.com/drugs/DB14787
    Investigational

    BMS-830216 is under investigation in clinical trial NCT00909766 (Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects).

  6. Drug

    Lucerastat

    go.drugbank.com/drugs/DB14872
    Investigational

    Lucerastat is under investigation in clinical trial NCT03425539 (Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease).

  7. Drug

    OPB-111077

    go.drugbank.com/drugs/DB16630
    Investigational

    OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation. It has demonstrated promising anticancer activity in preclinical models.

  8. Drug

    JZP-386 free base

    go.drugbank.com/drugs/DB17068
    Experimental

    Its safety, pharmacokinetics and pharmacodynamics were evaluated in clinical trial NCT02215499.

  9. Drug

    Emprumapimod

    go.drugbank.com/drugs/DB17603
    Investigational

    Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.

  10. Drug

    Befotertinib

    go.drugbank.com/drugs/DB18844
    Investigational

    Befotertinib is under investigation in clinical trial NCT05007938 (Befotertinib and Icotinib in Treatment-naive Patients With Advanced Egfr-mutant Lung Cancer).